Fedele, Vita
 Distribuzione geografica
Continente #
NA - Nord America 152
EU - Europa 116
AS - Asia 54
SA - Sud America 1
Totale 323
Nazione #
US - Stati Uniti d'America 151
CN - Cina 47
IE - Irlanda 26
IT - Italia 26
SE - Svezia 26
FR - Francia 16
DE - Germania 9
FI - Finlandia 7
UA - Ucraina 3
GB - Regno Unito 2
IN - India 2
AL - Albania 1
AM - Armenia 1
CA - Canada 1
CL - Cile 1
IL - Israele 1
KR - Corea 1
MY - Malesia 1
SA - Arabia Saudita 1
Totale 323
Città #
Chandler 38
Ashburn 31
Dublin 26
Jacksonville 10
Jinan 9
Helsinki 7
Wilmington 7
Lawrence 6
Princeton 6
Sindelfingen 6
Taiyuan 6
Beijing 5
Changsha 4
Verona 4
Washington 4
Redwood City 3
Dongguan 2
Haikou 2
Lanzhou 2
Milan 2
Nanjing 2
New York 2
Southend 2
Zhengzhou 2
Alfonsine 1
Bologna 1
Chaoyang 1
Chicago 1
Des Moines 1
Fairfield 1
Fuzhou 1
Hangzhou 1
Hebei 1
Houston 1
Kent 1
Nocera Inferiore 1
Riyadh 1
San Diego 1
Santiago 1
Seattle 1
Seoul 1
Shenyang 1
Taizhou 1
Tel Aviv 1
Tianjin 1
Tirana 1
Toronto 1
Yerevan 1
Totale 212
Nome #
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 73
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 69
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 61
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 47
Permissive State of EMT: The Role of Immune Cell Compartment 40
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 40
Totale 330
Categoria #
all - tutte 1.292
article - articoli 1.292
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.584


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 0 9
2020/202141 2 4 0 4 5 17 0 1 0 1 5 2
2021/202268 6 25 4 11 0 0 0 4 2 2 3 11
2022/2023132 6 16 12 17 10 37 1 10 18 2 3 0
2023/202480 3 3 9 11 10 16 12 6 1 6 3 0
Totale 330